Pliant Therapeutics
$1.32
62
+$0.05+4.37% Today
Statistics
Day High
1.33
Day Low
1.27
52W High
1.95
52W Low
1.09
Volume
293,856
Avg. Volume
782,106
Mkt Cap
80.81M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11MayExpected
Expected EPS
-0.356633
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-420.61MNet Income
Analyst Ratings
$2.67Average Price Target
The highest estimate is 3.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy 25%
Hold 50%
Sell 25%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PLRX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Galapagos NV
GLPG
Mkt Cap2.09B
Madrigal Pharmaceuticals
MDGL
Mkt Cap9.34B
Gilead Sciences
GILD
Mkt Cap148.78B
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Incyte
INCY
Mkt Cap18.35B
Abbvie
ABBV
Mkt Cap385.18B
About
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Show more...
CEO
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Employees
171
Country
US
ISIN
US7291391057
Listings
0 Comments
Share your thoughts
FAQ
What is Pliant Therapeutics stock price today?▼
The current price of PLRX is $1.32 USD — it has increased by +4.37% in the past 24 hours. Watch Pliant Therapeutics stock price performance more closely on the chart.
What is Pliant Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pliant Therapeutics stocks are traded under the ticker PLRX.
Is Pliant Therapeutics stock price growing?▼
PLRX stock has risen by +0.38% compared to the previous week, the month change is a +1.15% rise, over the last year Pliant Therapeutics has showed a -4.01% decrease.
What is Pliant Therapeutics market cap?▼
Today Pliant Therapeutics has the market capitalization of 80.81M
When is the next Pliant Therapeutics earnings date?▼
Pliant Therapeutics is going to release the next earnings report on May 11, 2026.
What were Pliant Therapeutics earnings last quarter?▼
PLRX earnings for the last quarter are -0.38 USD per share, whereas the estimation was -0.38 USD resulting in a -0.36% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Pliant Therapeutics revenue for the last year?▼
Pliant Therapeutics revenue for the last year amounts to 0 USD.
What is Pliant Therapeutics net income for the last year?▼
PLRX net income for the last year is -420.61M USD.
How many employees does Pliant Therapeutics have?▼
As of April 01, 2026, the company has 171 employees.
In which sector is Pliant Therapeutics located?▼
Pliant Therapeutics operates in the Health Care sector.
When did Pliant Therapeutics complete a stock split?▼
Pliant Therapeutics has not had any recent stock splits.
Where is Pliant Therapeutics headquartered?▼
Pliant Therapeutics is headquartered in South San Francisco, US.